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Methotrexate is the first line of treatment of rheumatoid arthritis. Since many patients become unresponsive to methotrex-
ate treatment, only very expensive biological therapies are effective and increased methotrexate tolerance strategies need
to be identified. Here we propose the encapsulation of methotrexate in a new liposomal formulation using a hydrophobic
fragment of surfactant protein conjugated to a linker and folate to enhance their tolerance and efficacy. In this study
we aim to evaluate the efficiency of this system to treat rheumatoid arthritis, by targeting folate receptor  present at
the surface of activated macrophages, key effector cells in this pathology. The specificity of our liposomal formulation
to target folate receptor  was investigated both in vitro as in vivo using a mouse model of arthritis (collagen-induced
arthritis in DBA/1J mice strain). In both systems, the liposomal constructs were shown to be highly specific and efficient
in targeting folate receptor . These liposomal formulations also significantly increase the clinical benefit of the encap-
sulated methotrexate in vivo in arthritic mice, together with reduced expression of CD39 and CD73 ectonucleotidases by
joint-infiltrating macrophages. Thus, our formulation might be a promising cost effective way to treat rheumatoid arthritis
and delay or reduce methotrexate intolerance.
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INTRODUCTION
Rheumatoid arthritis (RA) is a common chronic inflamma-
tory and destructive arthropathy that consumes consider-
able personal, social, and economic costs.12 It comprises
a syndrome of pain, stiffness, and symmetrical synovitis
of diarthrodial joints.3 Disease-modifying antirheumatic
drugs (DMARDs) slow disease progression and can induce
disease remission in some patients. Methotrexate (MTX)
is the most commonly prescribed DMARD.45 However,
the toxicity associated with low-dose MTX administration
is usually mild and self-limiting. Nausea without vomit-
ing and malaise are the most frequent adverse effects of
MTX treatment.67 Other effects include gastrointestinal
or bone marrow toxicity, pneumonitis, hepatotoxicity and
cirrhosis.8
Furthermore, many patients do not respond to MTX
treatment. If patients are MTX intolerant another DMARD
should be used or added, or alternatively biologic agents.4
In RA therapy biological agents used are anti-TNF-
molecules, responsible for the neutralization of TNF-,
the master regulator of RA immunopathogenesis. The
development of biological substances for the treatment of
rheumatic conditions has been accompanied by ongoing
health economic discussions regarding the implementation
of these highly effective, but accordingly, highly priced
drugs in the standard treatment guidelines of rheumatic
diseases.9 In this way, more efficient strategies have to
be identified in order to improve inflammatory disease
treatments while decreasing the MTX side effects with an
improved cost-benefit ratio.
We previously describe an innovative strategy for tar-
geted liposomal delivery that uses a hydrophobic frag-
ment of surfactant protein D (SP-D) conjugated to a linker
and folic acid (FA or folate), the SP-DS3 peptide, more
efficient than classic systems (polyethylene glycol, PEG,
linker).10
The biological evaluation and characterization of folate
receptor (FR)  targeting using these novel liposomal con-
structs demonstrates their capacity to carry and deliver
drugs to target cancer cells.
Although the etiology of RA remains controver-
sial, activated macrophages have been identified as key
mediators.1112 It is only after activation that macrophages
express the functional form of FR,1314 which binds the
vitamin FA with high affinity (Kd < 10−9 M). Here, we
aim to demonstrate the ability of our delivery system for
treatment of RA by targeting this macrophage receptor.
The biological evaluation and characterization of FR tar-
geting using these novel liposomal constructs demonstrates
their capacity to carry and deliver MTX to target activated
macrophages while not affecting normal cells, both in vitro
and in vivo. This was demonstrated in a pre-clinical mice
model of arthritis leading to a remarkable clinical benefit.
The novel tailored liposomes open new clinical avenues
for the diagnosis and treatment of human diseases includ-
ing chronic inflammatory diseases and cancer.
MATERIALS AND METHODS
Materials
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)
and N -(carbonyl methoxypolyethylene glycol-2000)-
1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE-
MPEG) were obtained from Lipoid GmbH (Germany).
Cholesterol (CH), fluorescein isothiocyanate (FITC) and
MTX were obtained from Sigma (USA). Alexa Fluor 647
was obtained from Invitrogen (USA).
Peptide Synthesis
The neck-domain peptide constructed from SP-D was syn-
thesized by American Peptide (USA). FA was covalently
bound at the N-terminus of the peptides via glutamic
acid and pteroic acid. Peptides were purified to greater
than 75% homogeneity, as determined by analytical high-
performance liquid chromatography, and characterized by
mass spectrometry.
Liposome Preparation
Liposomes were prepared using a thin film hydra-
tion method. The formulations produced are based on
DOPE/CH/DSPE-MPEG which may contain FA-peptide
for specific targeting and/or FITC/Alexa Fluor 647 for flu-
orescence labelling and/or MTX as drug (Table I). Briefly,
known amounts of DOPE, CH and DSPE-MPEG were dis-
solved in chloroform in a 50 mL round-bottom flask. For
macrophage internalization studies, FITC was incorporated
in the lipidic film.
The organic solvent was evaporated using a rotary evap-
orator followed by additional evaporation under reduced
pressure by a high-vacuum system to remove remaining
traces of chloroform. The resultant dried lipid film was
dispersed in phosphate buffered saline (PBS) buffer con-
taining either peptides, Alexa Fluor 647 or the MTX.
The mixture was vortex-mixed at a temperature greater
than the phase-transition temperature (room tempera-
ture) to yield multilamellar vesicles, which were then
extruded (extruder supplied by Lipex Biomembranes Inc.,
Canada) through 200 nm pore size polycarbonate filters
(Nucleopore, USA) followed by several passages through
100 nm polycarbonate filters (Nucleopore, USA) to form
large unilamellar vesicles. The free peptide, Alexa Fluor
647 and the MTX that was not incorporated into liposomes
was removed from the samples after passage through
a gel filtration chromatography column (GE Healthcare,
USA).
Table I. Different liposomal formulations prepared based on
DOPE/CH/DSPE-MPEG.
Target Fluorescent dye Fluorescent dye Drug
– FITC Alexa fluor 647 MTX
SP-DS3 FITC Alexa fluor 647 MTX
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Cell Culture Conditions
Human peripheral blood mononuclear cells were isolated
from buffy coats of blood donors from the Immuno-
haemotherapy Department of Hospital de São João (Porto,
Portugal) by centrifugation over Lymphoprep (Axis-
Shield, Norway), and monocytes were further purified by
magnetic cell sorting using CD14 microbeads (Miltenyi
Biotec, Germany). The ethics committee granted approval
for the study. Monocyte-derived macrophages were gen-
erated in RPMI 1640 (supplemented with 10% FCS,
100 U/mL penicillin and 100 g/mL streptomycin) in
the presence of 50 ng/mL M-CSF (PeproTech, UK) for
7 days followed by activation for 24 h with 20 ng/mL
IL-4 (PeproTech, UK). Jurkat E6.1 T cells and THP-1
cells were routinely cultivated in RPMI 1640 medium
supplemented with 10% FCS, 100 U/mL penicillin and
100 g/mL streptomycin. Four days prior to the lipo-
some uptake experiments, we transferred the cells to FA-
free RPMI 1640 medium supplemented with 10% FCS,
100 U/mL penicillin and 100 g/mL streptomycin. FR-
overexpressing THP-1 cells were prepared by retroviral
transduction of full-length human FR using an in-house
modified retroviral pBMN vector and subsequent FACS
sorting to obtain a 99.9% FR-positive population. THP-1
cells transduced with the empty vector were used as a
control.
Macrophage and T Cell Line Internalization
Binding and internalization of liposomes by macrophages
and T cells was assessed using a multi-spectral imaging
flow cytometer. Briefly, cells were incubated for 1 h with
100 g/mL liposomes in complete RPMI 1640 medium
at 37 C. After incubation, cells were washed twice with
PBS (pH 7.4). Surface FR was stained using a mono-
clonal FR antibody (Exbio, Czech Republic) after block-
ing Fc receptors with FcR Blocking Reagent (Miltenyi
Biotec, Germany). An isotype-matched monoclonal anti-
body was used as the negative control. Images of cells
were acquired on a 6-channel ImageStreamX Imaging
Flow Cytometer (Amnis, EMD Millipore) equipped with
488 nm and 785 nm excitation lasers, configured at 40×
magnification and controlled by INSPIRE software. Imag-
ing was performed at the Bioimaging Center for Biomate-
rials and Regenerative Therapies (b.IMAGE, INEB, Porto,
Portugal). Approximately 20,000 events were collected
per sample using a bright field (BF) area lower limit of
20 m2. Analysis was performed with IDEAS 5.0 (Amnis,
EMD Millipore). The percentage of cells with internal-
ized liposomes was determined using the Internalization
Wizard application of INSPIRE. Briefly, after excluding
out-of-focus images and selecting single cells, a gate was
drawn on the liposome-positive cells, and a mask corre-
sponding to the interior of the cell was created based on
the BF image. Internalization was estimated by comparing
the liposomal FITC fluorescence intensity inside the cell
with the fluorescence intensity in the entire cell, and the
percentage of cells with internalized liposomes was quan-
tified. Liposomal uptake was also measured using a LSRII
flow cytometer (BD) followed by analysis using FlowJo
software (TreeStar).
In Vivo Targeting of Liposomes to FR
Murine Macrophages
C57BL/6 mice were injected i.p. with zymosan (100 g,
Sigma). Three days later, Alexa Fluor 647-labelled
liposomes (200 l) were injected i.p., and peritoneal
macrophages were harvested at different time points. Fc
receptors were blocked by a 30 min incubation with nor-
mal goat and rabbit IgG (10 g/ml) in PBS/1% BSA. Cells
were stained in the same medium with a murine FR-
specific rat monoclonal antibody15 (kindly provided by
Dr. T. Matsuyama (Department of Immunology, Graduate
School of Medical and Dental Sciences, Kagoshima Uni-
versity, Japan) followed by a Dylight 488-conjugated anti-
rat secondary antibody (eBioscience, USA). Cells were
then stained for CD11b and F4/80 with CD11b-PE and
F4/80-PerCP Cy5 conjugates (eBiosciences, USA). Flow
cytometry data acquisition was performed using a FACS
Calibur cytometer (Becton Dickinson) and analyzed with
Kaluza software (Coulter).
Collagen-Induced Arthritis
Six-week-old DBA/1J Rj male mice were purchased from
Janvier Laboratory (Le Genest-St-Isle, France). Mice were
housed in groups of 6 per cage. Arthritis was induced
with type II bovine collagen (CII) (MD Bioscience,
Switzerland) as previously described.1617 Male DBA/1
mice were injected subcutaneously at the base of the
tail with 100 g of CII emulsified in Freund’s adjuvant
(BD DIFCO, Fisher Scientific, France). On day 21 post-
injection, mice were boosted with a subcutaneous injec-
tion of CII in incomplete Freund’s adjuvant (BD DIFCO,
Fisher Scientific, Ilkirch, France). In this model, arthri-
tis develops 20 to 30 days after the first collagen injec-
tion. Mice were monitored for evidence of arthritis in all
4 paws using a blind procedure. For each mouse, the clini-
cal severity of arthritis was scored (0: normal; 1: erythema;
2: swelling; 3: deformity; and 4: ankylosis) in 10 joints
or group of joints: 3 joints of the two hind legs (toes, tar-
sus, ankle). The maximum score reached for each of the
10 joints was 4, and thus, the maximum clinical arthritis
score for a single mouse on a given day was 40. The mean
arthritic score on each clinical observation day was cal-
culated in each group.18 The various injection treatments
were randomized in each cage to avoid cage dependency
of the clinical score, and a trained operator for arthritis
scoring (20 years) was blinded to the treatment injected
in each mouse. Treatment started 14 days after immuniza-
tion. The different formulations were injected twice per
week i.p., and mice were scored on the same day. For
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liposome in vivo uptake analysis, Alexa Fluor 647 fluo-
rescently labelled control or FA-SP-DS3 liposomes were
injected i.v. into the tails of arthritic mice showing similar
and high clinical scores (>10). Liposome uptake in ankles
was then monitored 30 min later by visualizing Alexa 647
fluorescence in living anesthetized animals using in vivo
fluorescence imaging (Photon imager RT, Biospacelab).
MTX was quantified after injection i.p. of 1.25 mg/kg,
and analysed via HPLCMSMS, (Agilent 1260 HPLC cou-
pled to a Sciex API4000 device triple quadrupole mass
spectrometer). MTX was detected in positive mode using
the +H molecular ion. These studies were approved by
the local animal experimentation ethics committee (CEEA
no. 34, agreement no. CEEA34.GB.029.11).
Statistical Analysis
Statistical analyses were performed with GraphPad Prism
software (version 5.0). Unless otherwise stated, differ-
ences were tested for statistical significance by a one-way
ANOVA.).
RESULTS
Cellular Uptake of Liposomes by
FR-Expressing Macrophages
We have previously described an innovative strategy for
targeted liposomal delivery that uses a hydrophobic frag-
ment of surfactant protein conjugated to a linker and
FA, the SP-DS3 peptide, more efficient than the clas-
sic systems.10 This peptide was shown to insert deeply
into the lipid bilayer without affecting the integrity of
the liposomes (0.75 molar ratio). The combination of all
complementary characteristics of these tailored liposomes,
including their small size (∼120 nm), low cytotoxicity and
their specific targeting of FR-expressing cells,10 supports
their use as specific therapeutic nanodelivery systems as
demonstrated here.
To evaluate the efficiency of FA targeting in lipo-
somes integrating a peptide conjugated to a linker and FA
(SP-DS3) we used activated human primary macrophages
derived from human peripheral blood monocytes cultured
in the presence of M-CSF because these cells express high
levels of FR. Macrophages expressing FR are impor-
tant cell targets for this type of delivery system as they
display a circumscribed distribution in many inflamma-
tory diseases and cancer.1920 It has been reported that
modifying the liposome surface with PEG greatly reduces
the immune recognition of the liposomes and their sub-
sequent clearance by the reticuloendothelial (mononuclear
phagocyte) system.2122 We therefore tested PEG at con-
centrations of 5% and 10% to improve the delivery speci-
ficity to activated FR-expressing macrophages. PEG at
10% greatly improved the stealth degree of the liposomes,
thereby reducing the non-specific uptake, and promoted
the specificity of FA-mediated targeting (Fig. 1(A)). An
increase in the percentage of SP-DS3 molecules, and con-
sequently amount of FA on the liposomal surface, further
improved this specific internalization (Fig. 1(A)). We also
measured the uptake of liposomes with the improved PEG
formulation in the monocytic cell line THP-1 with and
without the overexpression of human FR. Compared to
control liposomes, liposomes with FA were highly inter-
nalized in THP-1 cells retrovirally transformed with FR
in comparison with the wild-type THP-1 cells that weakly
express FR (data not shown) showing minimal uptake
similar to the Jurkat T cells used as a negative control
(Fig. 1(B)).
To test the specific targeting of activated macrophages
in vivo, FR-expressing macrophages were elicited by
intraperitoneal (i.p.) injection of zymosan into healthy
mice. Three days later, these mice were injected i.p.
with fluorescent liposomes for detailed uptake analysis.
Only peritoneal cells showing increased expression of the
CD11b and F4/80 macrophage markers expressed also
high levels of FR and a very high uptake of fluores-
cent liposomes (Fig. 1(C)). Compared to control liposomes
without FA, SP-DS3 liposomes exhibited high accumula-
tion in this subset of cells (Fig. 1(D)).
In Vivo Targeting of Liposomes to Arthritic Joints
To measure the in vivo uptake specificity of these new lipo-
somes in a pathological context, arthritis was induced in
DBA/1 mice using bovine type-II collagen (CIA model).
Arthritic mice, showing similar and high clinical scores,
were imaged after tail vein injection of FR-targeted
and non-targeted liposomes filled with Alexa Fluor 647.
Compared to liposomes without FA, SP-DS3 liposomes
strongly accumulated in the joints of the arthritic mice
(Fig. 2(A)). Of note in all mice a strong signal was also
observed at the sites of injection of the liposomes in the
tails. The mean fluorescence analysis in ankles of the two
groups shows a significantly higher uptake of liposomes-
FA (data not shown). Furthermore, we also monitored the
MTX concentration in the paws of CIA mice. MTX, first-
line drug therapy for the treatment of RA, was encapsu-
lated (∼750 g/mL) in liposomes. We observed a higher
level of MTX in the group treated with liposomes-FA, at
peak and also during the whole kinetics, demonstrating the
advantage of the SP-DS3 formulation.
We then measured the uptake of liposomes in cell pop-
ulations from inflamed joints of arthritic mice. To address
this point, we analyzed the cell populations within the
ankles using CD11b, F4/80 and FR markers. Three main
cell subsets can be clearly discriminated from CD11b and
F4/80 labeling. Among these, the CD11bint/F4/80hi cell
population showed the highest level of FR expression
(data not shown). By gating on these FR+macrophages,
we could not observe a higher percentage of Alexa
Fluor-647 positive cells. However, by analyzing the cells
expressing the highest levels of FR, we observed that the
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Figure 1. Specific uptake of liposomes by FR-expressing cells. Specific uptake of liposomes by (A) FR-expressing primary
human macrophages (1 h) and (B) monocytic THP-1 cell line over expressing human FR (24 h). (C) and (D) In vivo specific
targeting of liposomes to FR murine peritoneal macrophages. Histograms in C show that only CD11bhi F4/80hi macrophages
(L population) have uptaken the fluorescently-labeled liposomes. Graphs in D represent the increase of fluorescence in these
macrophages having internalized liposomes along time as determined by imaging flow cytometry analysis. Values are the
mean+SD of 2 experiments.
number of macrophages having uptaken FA-liposomes was
significantly higher in this cell subpopulation.
In Vivo Clinical Assays
In vivo evaluation of the clinical benefit of liposomal for-
mulations encapsulating MTX administered i.p. was per-
formed in arthritic mice, before disease onset. The results
indicate that encapsulation of MTX in liposome prepara-
tions can improve prophylactic efficacy (Figs. 2(C) and
(D)). The clinical benefit was significantly increased when
using SP-DS3 liposomes displaying FA, where mice did
not shown any clinical signs of disease, which is in good
agreement with the specific targeting observed in vitro and
the much stronger accumulation of MTX to the inflamed
joints when it is delivered encapsulated into FA-containing
liposomes. Comparatively, the drug injected in a soluble
form, it only had a marginal effect and did not prevent the
development of arthritis.
Studies have shown that cells of synovial fluid from
arthritic joints express the ectonucleotidases CD39 and
CD73,2324 both required to hydrolyze ATP in adenosine
and in turn limit inflammation. We therefore questioned
the status of these ectonucleotidases in macrophage popu-
lations in joints of CIA mice treated or not with liposomes.
To address this point ankles were digested in collagenase
and cell populations analyzed using CD11b, F4/80, FR,
CD39 and CD73 markers. After a first gating on CD11b
and F4/80 cells to select macrophages (CD11bint F4/80hi,
a second gate on FR expression was defined (Fig. 3(A)).
We found that expression of the ectonucleotidases CD73
and CD39 was decreased about 2-fold in this joint tissue
macrophage population harvested from mice treated with
FA-liposomes containing MTX compared with liposomes
without FA and MTX (Figs. 3(B) and (C)). We observed
intermediate levels of CD39 and CD73 in FA-liposomes
treated mice, suggesting an effect of the liposomes just by
targeting the FR. We also showed that the expression of
FR also tends to decrease similarly (Fig. 3(D)).
CD39 and CD73 ectonucleotidase expression levels
were also analyzed in relation to FR expression. We
observed that their expression correlated with FR expres-
sion levels (Figs. 4(A) and (B)). The expression levels of
CD39 and CD73 were also correlated to the clinical score
for each posterior leg or to the total clinical score, the
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Figure 2. In vivo specific targeting and prophylactic efficiency of FR-targeted liposomes in arthritic mice. In vivo uptake speci-
ficity of (A) Alexa Fluor 647 fluorescently labelled liposomes (30 min) and (B) liposomes encapsulating MTX (following i.p.
application of 1.25 mg/kg MTX). (C) Clinical effects of liposomes encapsulating MTX on arthritis. The mean clinical score in
each group (12 mice/group) over time is shown. A Dunn’s multiple comparison test was performed (P value < 005). (D) Mean
clinical scores+SD from two independent experiments performed as in (C) are shown. Unpaired two-tailed t test was performed
(P value= 0006).
latter taking into account clinical scores of both poste-
rior and anterior legs. As shown in Figures 5(A) and (B),
high clinical scores translate directly into higher levels of
CD73, when either leg or total clinical scores are consid-
ered. The same observation was made concerning CD39
(Figs. 5(C) and S(D)). Importantly, treatment of mice with
FA-liposomes led to an intermediary total clinical score
that accords to an intermediary average level of CD39 or
CD73 (Figs. 5(B) and (D)).
DISCUSSION
The drugs presently used in RA treatment are often inef-
fective and frequently present serious side effects that
can even lead to the death of the patient. Despite their
high clinical effectiveness, the cost efficacy of biologicals
agents, namely anti-TNF- molecules, is questionable.
Therefore it is imperative the development of alternative,
cost efficient treatment for RA, with low side effects,
that will constitute a more advantageous solution than
current therapies. In earlier studies of RA, in inflamed
joints, a subpopulation of activated macrophages was
observed which also expresses a receptor for the FA
vitamin. Because no other tissues/cell types expressed
the FR (except the kidneys proximal tubules and pla-
centa and in normal hematopoietic tissue), accumula-
tion of FR-macrophages in arthritic joints allowed the
selective targeting of FA linked imaging and therapeu-
tic agents to these sites of inflammation.25 FA-targeted
therapies, selectively attack the pathologic cell type, leav-
ing the vast majority of macrophages unharmed. As a
consequence, the level of toxicity associated with FA-
targeted therapy appears to be very low.11 Recently, Low
and colleagues developed an antibody with high speci-
ficity towards human FR and demonstrated that this
antibody is able to target FR positive cells including
macrophages from RA patients.26 Likewise, other efforts
in therapy include dsFv anti-FR-targeted Pseudomonas
exotoxin A,27 FA hapten-mediated immunotherapies2829
and anti-FA designed to bind FR.30 These findings sug-
gest that FR therapies can be applied as a research
tool for effective targeting of activated macrophages dur-
ing inflammatory disease progression. This observation,
together with the observation that arthritic joints are read-
ily visualized with FA-targeted radiopharmaceuticals in
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Figure 3. CD73, CD39 and FR expression by joint tissue macrophages depending on treatment of CIA mice with liposomes.
(A) Gating strategy. Ankles were removed from CIA mice which received liposomes. Cells were stained with anti-CD11b, anti-F4/80,
anti-CD73, anti-CD39 and FR antibodies. Expression of CD73, CD39 and FR was analyzed on CD11bint/F4/80hi macrophage cell
population (gate C). Mean fluorescence intensities of CD 73 (B), CD39 (C) and FR (D) in gate C after the different treatments are
shown. Statistical values (Student’s test analysis) are also shown.
patients with RA (18F-polyethylene, PET tracer31 and
glycol-folate99mTc-EC20, FolateScan32, promises well for
a successful response to FA-targeted immunotherapy in
humans. Although each of the aforementioned approaches
holds promise for yielding new therapeutic options for
patients, there have been no reports for FR-mediated
targeting anti-inflammatory drugs to sites of inflamma-
tion, encapsulated in drug delivery systems. Recently,
Thomas T. and colleagues developed a FA-conjugated
Figure 4. Correlation of CD73 (A) and CD39 (B) expression levels with FR expression by joint tissue macrophages depending
on treatment of CIA mice with liposomes. Ankles were removed from CIA mice which received liposomes. CD73, CD39 and FR
membrane levels were measured by FACS as described in Figure 3. Each dot represents one ankle from a separate mouse.
dendrimers to target macrophages in inflammatory disease
of arthritis.33 However, the surface conjugation of de drug
MTX prevents their protection from degradation or deacti-
vation prior to reaching target site in vivo. Liposomes have
gained extensive attention as carriers for a wide range of
drugs due being both nontoxic and biodegradable because
they are composed of naturally occurring substances.3435
Biologically active materials encapsulated within lipo-
somes are protected to varying extent from immediate
J. Biomed. Nanotechnol. 11, 2243–2252, 2015 2249
Enhancing Methotrexate Tolerance with Folate Tagged Liposomes in Arthritic Mice Nogueira et al.
Figure 5. CD39 and CD73 macrophage expressions correlate with clinical scores. CD73 and CD39 expressions of
CD11b+intF4/80hi macrophages harvested from ankles used in Figure 4 were correlated with the clinical score of each joint
(A and C, respectively) or the total clinical scores (B and D, respectively).
dilution or degradation, suggesting drug carrier systems
for the transport of drugs and other bioactive capsules to
disease affected organs.36–38 We have developed a novel
FR-targeted liposomes by incorporating a bifunctional SP-
DS3 peptide consisting of the neck domain of surfactant
proteins, which serves both as a linker and an anchor of
the FA to the liposomal membrane. This delivery system
proved to be more efficient than classic systems where
the FA is linked to liposomes by PEG. The combination
of all complementary characteristics of these tailored lipo-
somes, including their small size, lack of cytotoxicity and
their specific targeting of FR-expressing cells, supports
their use as specific therapeutic nanodelivery systems as
demonstrated here by the biological effect of several drugs.
The exciting results obtained with FR cancer cells led us
to investigate their use in FR expressing cells, namely
activated macrophages, the key effector cells in RA. The
inclusion of PEG in liposomal bilayers has extended blood
circulation time of conventional liposomes and is con-
sidered as a major breakthrough in liposome mediated
drug delivery.22 The results show that the presence of 5%
PEG was insufficient to reduce the internalization of lipo-
somes by activated human primary macrophages.21 The
increase to 10% PEG greatly improved the stealth degree
of the liposomes, thereby reducing the non-specific uptake,
and promoted the specificity of FA-mediated targeting.
The low internalization of FA-bearing liposomes in cells
with negligible FR expression (THP-1 macrophages and
Jurkat T cells) compared to macrophages overexpressing
FR (THP-1 retrovirally transformed to overexpress FR
demonstrated that their uptake by immune cells is depen-
dent on FR expression. Furthermore, the results obtained
in activated macrophages in vivo clearly demonstrate the
potential of these novel liposomes that integrate SP-DS3
to target FR-expressing macrophages.
To test the specificity of these new liposomes in a
pathological context, arthritis was induced in mice (CIA
model), and the results showed that liposomes strongly
accumulated in their joints. Furthermore, the analysis of
cell populations from inflamed joints of arthritic mice
revealed that macrophages expressing high levels of FR
are more prone to uptake FR-targeted than the non-targeted
liposomes.
To prove the ability of our liposomal formulation as
drug delivery system, liposomes encapsulating MTX were
administered in arthritic mice, before disease onset. Com-
plete prophylactic efficacy was observed in mice treated
with SP-DS3 liposomes encapsulating MTX, where mice
did not shown any clinical signs of arthritis. Compara-
tively, when the drug was injected in a soluble form it only
had a marginal effect and did not prevent the development
of arthritis. This fact lead us to believe that encapsulation
of MTX in our proposed formulation offers a cost effective
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way to treat arthritis and delay or reduce MTX intoler-
ance. The results presented here might have an important
implication in clinical practice, where available biologi-
cal therapies could be delayed or completely replaced by
the proposed MTX liposomal formulations tested in this
work. It brings new hope to a large number of patients
who become intolerant to MTX and require much more
expensive treatments with biological agents.
It was found that the ectonucleotidases CD39 and CD73,
required to hydrolyze ATP in adenosine and in turn limit
inflammation, are express in cells of synovial fluid from
arthritic joints. In good agreement with this observation,
our results show that the presence of CD39+ CD73+
FR+ expressing macrophages is correlated with a high
clinical score. Moreover, this cell population is less abun-
dant in arthritic mice treated with liposomes containing
FA, especially when MTX was encapsulated in the device.
Thus, efficiency of our liposomal formulation in RA treat-
ment might be the direct consequence of this regula-
tion of CD39 and CD73 ectonucleotidase expression by
macrophages.
In conclusion, the use of liposomes equipped with the
novel bifunctional SP-DS3 peptide linker for FA-mediated
delivery opens new opportunities for the cost-effective
treatment of human chronic inflammatory diseases as RA.
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